SOUTH SAN FRANCISCO, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Exelixis, Inc. will release its third quarter 2006 financial results on Thursday, November 2, 2006 after the markets close.
The announcement will be followed by a live webcast at 2:00 p.m. PT/5:00 p.m. ET of a discussion by Exelixis management of the third quarter 2006 financial results and general business update. The webcast may be accessed in the Event Calendar page under Investors at www.exelixis.com.
An archive of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on December 2, 2006. Access numbers for this replay are: 1-877-660-6853 (domestic) and 1-201-612-7415 (international); Account number is 286; Conference ID number is: 217162.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in Phase III (XL119, exclusively out-licensed to Helsinn Healthcare S.A), Phase II, and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech and Sankyo. For more information, please visit the company’s web site at www.exelixis.com.
Exelixis, Inc.
CONTACT: Investor Contact, Charles Butler, Director of CorporateCommunications, +1-650-837-7277, or cbutler@exelixis.com, or Media Contact,Soleil Maxwell Harrison, Senior Manager of Corporate Communications,+1-650-837-7012, or sharrison@exelixis.com, both of Exelixis, Inc.
Web site: http://www.exelixis.com/
